SOX10 expression in malignant melanoma, carcinoma,and normal tissues

Applied Immunohistochemistry and Molecular Morphology

Volumn 21, Issue 6, 2013, Pages 506-510

  Mohamed, Amr ^b   Gonzalez, Raul S ^a   Lawson, Diane ^a   Wang, Jason ^a   Cohen, Cynthia ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

Carcinoma; Melanoma; Normal tissues; Sox 10

Indexed keywords

TRANSCRIPTION FACTOR SOX10;

ARTICLE; BREAST CARCINOMA; CARCINOMA; CYTODIAGNOSIS; DESMOPLASTIC MELANOMA; DYSPLASTIC NEVUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JUVENILE MELANOMA; MELANOMA; METASTATIC MELANOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY;

BREAST NEOPLASMS; CARCINOMA; CASE-CONTROL STUDIES; COLONIC NEOPLASMS; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MELANOMA; NEVUS; OVARIAN NEOPLASMS; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; SOXE TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84882867735     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e318279bc0a     Document Type: Article

References (28)

1. Pusch C, Hustert E, Pfeifer D, et al. The SOX10/Sox10 gene from human and mouse: sequence, expression, and transactivation by the encoded HMG domain transcription factor. Hum Genet. 1998;103:115-123.
2. Mollaaghababa R, Pavan WJ. The importance of having your SOX on: role of SOX10 in the development of neural crest-derived melanocytes and glia. Oncogene. 2003;22:3024-3034.
3. Bondurand N, Kobetz A, Pingault V, et al. Expression of the SOX10 gene during human development. FEBS Lett. 1998;432: 168-172.
4. Kuhlbrodt K, Herbarth B, Sock E, et al. Sox10, a novel transcriptional modulator in glial cells. J Neurosci. 1998;18:237-250.
5. Nonaka D, Chiriboga L, Rubin BP. Sox10: A pan-schwannian and melanocytic marker. Am J Surg Pathol. 2008;32:1291-1298.
6. Bowles J, Schepers G, Koopman P. Phylogeny of the SOX family of developmental transcription factors based on sequence and structural indicators. Dev Biol. 2000;227:239-255.
7. Britsch S, Goerich DE, Riethmacher D, et al. The transcription factor Sox10 is a key regulator of peripheral glial development. Genes Dev. 2001;15:66-78.
8. Sanchez-Mejias A, Watanabe Y, M Fernández R, et al. Involvement of SOX10 in the pathogenesis of Hirschsprung disease: report of a truncating mutation in an isolated patient. J Mol Med (Berl). 2010;88:507-514.
9. Stanchina L, Van De Putte T, Goossens M, et al. Genetic interaction between Sox10 and Zfhx1b during enteric nervous system development. Dev Biol. 2010;341:416-428.
10. Harris ML, Baxter LL, Loftus SK, et al. Sox proteins in melanocyte development and melanoma. Pigment Cell Melanoma Res. 2010;23: 496-513.
11. Cook AL, Smith AG, Smit DJ, et al. Co-expression of SOX9 and SOX10 during melanocytic differentiation in vitro. Exp Cell Res. 2005;308:222-235.
12. Severi G, Giles GG, Robertson C, et al. Mortality from cutaneous melanoma: evidence for contrasting trends between populations. Br J Cancer. 2000;82:1887-1891.
13. Hall HI, Miller DR, Rogers JD, et al. Update on the incidence and mortality from melanoma in the United States. J Am Acad Dermatol. 1999;40:35-42.
14. Scheier B, Amaria R, Lewis K, et al. Novel therapies in melanoma. Immunotherapy. 2011;3:1461-1469.
15. Perry MD, Gore M, Seigler HF, et al. Fine needle aspiration biopsy of metastatic melanoma. A morphologic analysis of 174 cases. Acta Cytol. 1986;30:385-396.
16. Perry MD, Seigler HF, Johnston WW. Diagnosis of metastatic malignant melanoma by fine needle aspiration biopsy: A clinical and pathologic correlation of 298 cases. J Natl Cancer Inst. 1986;77: 1013-1021.
17. Sheffield MV, Yee H, Dorvault CC, et al. Comparison of five antibodies as markers in the diagnosis of melanoma in cytologic preparations. Am J Clin Pathol. 2002;118:930-936.
18. Mahmood MN, Lee MW, Linden MD, et al. Diagnostic value of HMB-45 and anti-Melan A staining of sentinel lymph nodes with isolated positive cells. Mod Pathol. 2002;15:1288-1293.
19. Ohsie SJ, Sarantopoulos GP, Cochran AJ, et al. Immunohistochemical characteristics of melanoma. J Cutan Pathol. 2008;35: 433-444.
20. Jing X, Michael CW, Theoharis CG. The use of immunocytochemical study in the cytologic diagnosis of melanoma: evaluation of three antibodies. Diagn Cytopathol. 2011. doi: 10.1002/dc.21791. [Epub ahead of print].
21. Friedman HD, Tatum AH. HMB-45-positive malignant lymphoma. A case report with literature review of aberrant HMB-45 reactivity. Arch Pathol Lab Med. 1991;115:826-830.
22. Orchard GE. Comparison of immunohistochemical labelling of melanocyte differentiation antibodies melan-A, tyrosinase and HMB 45 with NKIC3 and S100 protein in the evaluation of benign naevi and malignant melanoma. Histochem J. 2000;32: 475-481.
23. Schaumburg-Lever G, Metzler G, Kaiserling E. Ultrastructural localization of HMB-45 binding sites. J Cutan Pathol. 1991;18: 432-435.
24. Kocan P, Jurkovic I, Bö ö r A, et al. Immunohistochemical study of melanocytic differentiation antigens in cutaneous malignant melanoma. A comparison of six commercial antibodies and one noncommercial antibody in nodular melanoma, superficially spreadingmelanoma and lentigo maligna melanoma. Cesk Patol. 2004;40:50-56.
25. Kaufmann O, Koch S, Burghardt J, et al. Tyrosinase, melan-A, and KBA62 as markers for the immunohistochemical identification of metastatic amelanotic melanomas on paraffin sections. Mod Pathol. 1998;11:740-746.
26. Kazakov DV, Kutzner H, Rü tten A, et al. The anti-MAGE antibody B57 as a diagnostic marker in melanocytic lesions. Am J Dermatopathol. 2004;26:102-107.
27. Miller DD, Emley A, Yang S, et al. Mixed versus pure variants of desmoplastic melanoma: A genetic and immunohistochemical appraisal. Mod Pathol. 2012;25:505-515.
28. Ramos-Herberth FI, Karamchandani J, Kim J, et al. SOX10 immunostaining distinguishes desmoplastic melanoma from excision scar. J Cutan Pathol. 2010;37:944-952.